

NeuroNova


Developing Disease Modifying Treatments in CNS

Sweden Bio - March 2010



Reversing the Progression of Parkinson's Disease

– *The Second Largest Neurodegenerative Disease*




The objective is to reverse the progression of Parkinson's Disease and thereby "set the disease back in time".

sNN0031 for Parkinson's Disease

– *Potentially Disease-modifying Treatment*

- sNN0031 induces the formation of new brain cells from resident progenitor cells in the brain
- sNN0031 is rhPDGF-BB formulated for intracerebroventricular CNS administration
- Protected through proprietary and licensed Intellectual Property




Ongoing phase I/II clinical trial

- *Objective:*
 - *Safety and tolerability with efficacy parameters*
- *Drug:*
 - *Three dose levels and placebo*
- *Patients:*
 - *Moderate disease stage*
- *Results:*
 - *Due Q4, 2010*



Halting Progression of ALS (Lou Gehrig's Disease)

– An Orphan Neurodegenerative Disease



The objective is to counter-act the progression of ALS and thereby prolong life through continuous treatment with sNN0029



Summary of sNN0029 for ALS/Lou Gehrig's Disease

- rhVEGF has neuroprotective properties
- sNN0029 is rhVEGF formulated for CNS administration
- License agreement with Genentech Inc.
 - North American territory option for Genentech Inc. (Roche)
 - Ex-north American territory for NeuroNova
 - Opt-in fee/milestone/royalty arrangement



Ongoing phase I/II clinical trial sNN0029

- *Objective:*
 - *Safety and tolerability with efficacy parameters*

- *Drug:*
 - *Three dose levels and placebo (n=28)*

- *Design:*
 - *Part A: Open (done)*
 - *Part B: Blinded, placebo-controlled (ongoing)*

- *Results*
 - *due Q4, 2010*



NeuroNova – Summary

- Novel therapies for Parkinson’s Disease and ALS in clinical development
- Treatments potentially halting (ALS) and reversing (Parkinson’s Disease) the disease progression
- Direct delivery of biotherapeutics to central parts of the brain
- Collaborations with Medtronic, Genentech (Roche) and Novartis

Genentech
IN BUSINESS FOR LIFE



Medtronic



NOVARTIS

- Largest shareholders (who would like to be joined by others)

Investor

HealthCap

